DoW Tuberous Sclerosis Complex, Clinical Translational Research Award
Supports clinical translational research to move promising preclinical or clinical findings closer to diagnosis, prognosis, or treatment of tuberous sclerosis complex (TSC) for eligible applicants.
⚑ Multiple-PIs allowed; only the initiating PI submits the pre-application, but all PIs must submit linked full applications. · Associated applications may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. · Military/DoD topic-specific clinical translational research program for TSC.
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds applied research |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).
Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Apply
View on Grants.gov → CONTACT: JoAnn Martin Grantor <help@eBRAP.org>